Human Placental Derived Stem Cell
Niemann-Pick Disease
New York Medical CollegeCell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Niemann-Pick Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
Duoc-01 Joanne Kurtzberg, MD | Phase 1 | CC |
WATER O 15 National Institute of Neurological Disorders and Stroke (NINDS) | D | |
ogt918 National Eye Institute (NEI) | Phase 1 | NR |
Olipudase Alfa Sanofi | Phase 2/3 | NR |
Same molecule, other indications
Human Placental Derived Stem Cell is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →